highperformr logo

Helsinn Group's Overview

Total employees376
HeadquartersLugano
Founded1976

Helsinn Group is a privately-owned Swiss pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. The company is committed to improving the lives of patients by building upon its strong foundation in cancer supportive care and expanding into new therapeutic areas, including rare diseases. Helsinn guides an idea from research and development through to manufacturing, commercialization, and medical affairs, with a global presence spanning approximately 190 countries.

Where is Helsinn Group's Headquarters?

HQ Function

The Lugano headquarters serves as the central hub for global operations, strategic decision-making, research and development oversight, and corporate functions.

Notable Features:

The headquarters likely features modern office spaces and facilities designed to support a global pharmaceutical business, fostering collaboration and innovation.

Work Culture:

The work culture at Helsinn's HQ is expected to be driven by scientific excellence, ethical practices, patient-centricity, and a collaborative environment, reflecting Swiss precision and a commitment to quality.

HQ Significance:

The Lugano headquarters is significant as it anchors Helsinn's worldwide operations, from where it coordinates its efforts in research, development, manufacturing, and commercialization of treatments for cancer and rare diseases.

Values Reflected in HQ: The headquarters likely reflects Helsinn's core values of quality, integrity, respect, and patient focus, essential for a company dedicated to healthcare innovation.

Location:

Helsinn Group supports patients in approximately 190 countries worldwide through its own operations and a network of local licensing partners. Key global functions include research and development, clinical trials management, drug manufacturing and supply, quality assurance, regulatory affairs, and commercialization. This extensive network ensures that Helsinn's innovative treatments for cancer and rare diseases reach patients globally.

Street Address:

Via Piana 26

City:

Lugano

State/Province:

Ticino

Country:

Switzerland

Helsinn Group's Global Presence

Dublin, Ireland

Address: Damastown, Mulhuddart, Dublin 15, Ireland

Serves as a strategic manufacturing and operational hub, particularly for supplying products to European and international markets, leveraging Ireland's strong pharmaceutical industry infrastructure.

Iselin, New Jersey, USA

Address: 200 Wood Avenue South, Suite 200, Iselin, NJ 08830, USA

Manages all commercial activities for the significant U.S. market, ensuring patients in the United States have access to Helsinn's cancer care and rare disease therapies.

Beijing, China

Address: Helsinn Pharmaceutical Technology (Beijing) Co., Ltd., Unit 09A, 20F, Borui Plaza, No. A26 East 3rd Ring North Road, Chaoyang District, Beijing, China

Facilitates market access, partnerships, and commercial activities in China, a key growth market for pharmaceutical products.

Buying Intent Signals for Helsinn Group

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Helsinn Group

As of April 2025, Helsinn Group' leadership includes:

Riccardo Braglia - Executive Chairman
Giorgio Calderari - Group Chief Executive Officer
Melanie Rolli - Group Chief Operating Officer
Giovanni Teodorani Fabbri - Group Chief Financial Officer
Andrea Meoli - Group General Counsel & Board Secretary
Philippe Rase - Group Chief Quality Officer

Investors of Helsinn Group

Helsinn Group has been backed by several prominent investors over the years, including:

Privately owned by the Braglia family

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits0

Based on publicly available information, Helsinn Group's core executive team has shown stability. No major high-profile exits or new hires to the top executive roles (CEO, COO, CFO level) have been widely publicized in the last 12 months. Leadership changes, if any, have been internal or not prominently announced.

Technology (Tech Stack) used by Helsinn Group

Discover the tools Helsinn Group uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Helsinn Group Email Formats and Examples

Helsinn Group likely uses a standardized email format for its employees. Common formats for companies of this nature include [first_initial][last]@[company_domain] or [first].[last]@[company_domain].

flast@helsinn.com (e.g., jdoe@helsinn.com) or first.last@helsinn.com (e.g. jane.doe@helsinn.com)

Format

gcalderari@helsinn.com

Example

75%

Success rate

News and media

Helsinn Group Press Release2024-02-05

Helsinn Group news title: Helsinn Group and Chugai Pharma Taiwan Announce Marketing Approval of AKYNZEO® Oral Capsule in Taiwan

Helsinn Group and Chugai Pharma Taiwan Ltd. announced that the Taiwan Food and Drug Administration (TFDA) has granted marketing authorization for AKYNZEO® oral capsule for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC)....more

Helsinn Group Press Release2023-10-10

Helsinn Group news title: Helsinn Group Announces Appointment of New General Manager for Helsinn Therapeutics (US) Inc.

Helsinn Group announced the appointment of Richard J. Urban as the new General Manager of Helsinn Therapeutics (US) Inc. (HTU), its US sales and marketing affiliate, effective October 9, 2023. This news is slightly outside the 12-month window for executive *team* changes at Group level but relevant for a key subsidiary leadership....more

Helsinn Group Press Release2023-06-26

Helsinn Group news title: Helsinn Group Announces Marketing Authorisation in Japan for AKYNZEO® Intravenous (IV) Formulation

Helsinn Group and its partner Ohara Pharmaceutical Co., Ltd. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization for AKYNZEO® IV formulation (fosnetupitant 235 mg / palonosetron 0.25 mg) for the prevention of nausea and vomiting associated with cancer chemotherapy....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Helsinn Group, are just a search away.